Brand name: Duavive 0.45/20 TM
Active ingredients: conjugated estrogens + bazedoxifene
What it is used for
DUAVIVE is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- DUAVIVE should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- Experience in women older than 65 years is limited.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Store in Original Container
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A pink, oval shaped, tablet marked on one side with 0.45/20
Images are the copyright of Medicines Information Pty Ltd
We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Over 65?
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient conjugated estrogens + bazedoxifene
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems